U.S., June 12 -- ClinicalTrials.gov registry received information related to the study (NCT07015697) titled 'A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors' on June 03.
Brief Summary: This is a dose escalation, and dose expansion study of T-DXd plus hyaluronidase administered subcutaneously, to assess the safety, tolerability, PK and efficacy of SC T-DXd plus hyaluronidase in participants with metastatic solid tumors.
Study Start Date: June 30
Study Type: INTERVENTIONAL
Condition:
Recurrent or Metastatic Solid Tumors
Intervention:
DRUG: Trastuzumab Deruxtecan
Dose Escalation Part: Trastuzumab Deruxtecan will be administered at escalating doses to determine the RDE.
Expansion Part: Trastu...